Abstract
The discovery and optimization of potent and selective aminobenzimidazole glucagon receptor antagonists are described. One compound possessing moderate pharmacokinetic properties in multiple preclinical species was orally efficacious at inhibiting glucagon-mediated glucose excursion in transgenic mice expressing the human glucagon receptor, and in rhesus monkeys. The compound also significantly lowered glucose levels in a murine model of diabetes.
MeSH terms
-
Administration, Oral
-
Animals
-
Benzimidazoles / chemistry*
-
Benzimidazoles / pharmacokinetics
-
CHO Cells
-
Chemistry, Pharmaceutical / methods
-
Cricetinae
-
Cricetulus
-
Diabetes Mellitus, Experimental / metabolism
-
Glucagon / chemistry
-
Humans
-
Inhibitory Concentration 50
-
Macaca mulatta
-
Mice
-
Mice, Transgenic
-
Receptors, Glucagon / antagonists & inhibitors*
-
Receptors, Glucagon / chemistry*
Substances
-
Benzimidazoles
-
Receptors, Glucagon
-
Glucagon